1 **Analysis: The potential health and economic impact of dexamethasone treatment for** 2 **patients with COVID-19**

3 Ricardo Águas, Adam Mahdi, Rima Shretta, Peter Horby, Martin Landray, Lisa White*,
4 and the CoMo Consortium**

6 * Corresponding author: lisa.white@ndm.ox.ac.uk

7 ** See annex for full list of authors

9 **Abstract**

10 Dexamethasone has been shown to reduce mortality in hospitalised COVID-19 patients
11 needing oxygen and ventilation by 18% and 36%, respectively. Here, we estimate the
12 potential number of lives saved and life years gained if this treatment would be rolled out in
13 the UK and globally, as well as its cost-effectiveness of implementing this intervention. We
14 estimate that, for the UK, approximately 12,000 [4,250 - 27,000] lives could be saved by
15 January 2021. Assuming that dexamethasone has a similar effect size in settings where
16 access to oxygen therapies is limited, this would translate into approximately 650,000
17 [240,000 - 1,400,000] lives saved globally. If dexamethasone acts differently in these
18 settings, the impact could be less than half of this value. To estimate the full potential of
19 dexamethasone in the global fight against COVID-19, it is essential to perform clinical
20 research in settings with limited access to oxygen and/or ventilators, e.g. in low and middle-
21 income countries.

23 Coronavirus disease 2019 (COVID-19), emerged in late 2019 and is either asymptomatic or
 24 causes only mild symptoms in most individuals². However, a significant number of
 25 individuals, especially amongst the elderly, develop a more severe form of the disease and
 26 require hospital care. A further subset of these patients requires oxygen therapy or
 27 ventilatory assistance, creating a high demand for long-term hospital care in intensive care
 28 units (ICUs). In the UK, the case fatality rate among those admitted to hospital with COVID-
 29 19 is more than 26%; this rises to more than 37% in patients who require mechanical
 30 ventilation³. An extensive search for potential drugs with which to treat COVID-19 is
 31 underway. Dexamethasone has emerged as a standout therapeutic candidate reducing
 32 mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and
 33 36%, respectively¹. Thus, the adoption of a dexamethasone treatment protocol for patients
 34 requiring respiratory support could potentially lead to a significant number of lives saved
 35 over the course of the next 6 months of the pandemic.

36 Lockdown measures are being eased around the world, creating concern about potential
 37 resurgences in COVID-19⁴ activity. As stringent transmission-reducing interventions are
 38 lifted, the expectation is that a second epidemic peak becomes inevitable, and with it a
 39 significant increase in mortality. Dexamethasone is an affordable medicine available as a
 40 generic product that has been routinely used in hospital settings globally and is thus,
 41 assuming global availability is maintained⁵, perfectly placed as a candidate standard
 42 therapeutic option for COVID-19 patients with respiratory distress, which could significantly
 43 reduce the future mortality burden of this disease in a cost-effective way.

44

45 ***COVID-19 exposure and mortality in the UK***

Estimates of the future burden of COVID-19, and therefore the impact of any treatments for COVID-19, are highly dependent both on viral and human behavioural factors. Both are riddled with uncertainty and are changing as the pandemic evolves. Several biological parameters describing how the virus transmits between individuals and how infectivity progresses following infection remain elusive. A critical metric that reflects both how transmissible and lethal the virus can be is the infection fatality ratio (IFR). Until very recently, obtaining a clear picture of how many people have been infected was only feasible in small, well contained outbreaks, such as those on cruise ships⁶. Even in those instances, the narrow time window for good Polymerase Chain Reaction (PCR) testing sensitivity meant even the best estimates for IFR were changing on a weekly basis. Establishing the relationship between deaths and infections is crucial to enable reliable mortality burden predictions for the next wave of the epidemic.

Since May 2020, serological studies have been conducted, in several countries, to measure the proportion of the population that has been exposed to the virus, including in the UK⁷.

We now know that at least 7% of the UK population has been exposed to COVID-19, while around 40,000 patients have died from the disease⁸. Of these patients, if 59% had received oxygen and 17% had been ventilated¹ then, using the reported reduction in mortality risk¹, approximately 6,700 individuals would have survived had they been given dexamethasone, according to this simple calculation: $[(0.18 \times 0.59) + (0.36 \times 0.17)] \times 40,000 = 6,696$.

Given a reasonable IFR estimate, we can project different SARS-COV-2 transmission progression scenarios for the next 6 months, along with their respective mortality burdens, notwithstanding a great deal of uncertainty around what future social distancing measures will be taken and how the population will adhere to those measures. Here, we describe a simple and transparent approach to determine the potential benefits of implementing a

standard COVID-19 treatment protocol with dexamethasone in terms of lives saved, life years gained, and cost per life saved. In simple terms, given a country's population age structure, we use age-dependent estimates for the relationships between infection and mortality and infection and hospitalisation to extrapolate the expected number of hospital admissions and COVID-19 deaths given a specific projected number of infections over the next 6 months. Assumptions about oxygen treatment requirements and expected probabilities of mortality given the use of dexamethasone are clearly stated and can be altered to explore alternative options for these values.

Results

Potential lives saved with dexamethasone treatment

We consider the treatment of patients hospitalised with COVID-19 disease, as defined in³ as when a patient presents with (i) typical symptoms (e.g. fatigue with fever and muscle pain, or respiratory illness with cough and shortness of breath); and (ii) compatible chest X-ray findings (consolidation or ground-glass shadowing); and (iii) alternative causes have been considered unlikely or excluded (e.g. heart failure, influenza). However, the diagnosis remains mainly based on clinical symptoms and is ultimately at the managing doctor's discretion.

Working from the population age distribution in the UK as reported by the UN 2019 Revision of World Population Prospects⁹, we assume that among those who are infected, the proportion hospitalised is as estimated for the French population¹⁰. We also assume that the hospitalised case fatality ratio by age is correlated with that estimated for the French population¹⁰. More specifically, we developed a hospitalised patient treatment pathway

93 similar to the one in¹¹, which can be distilled into a decision tree algorithm (Figure 1) driven
 94 by the parameters listed in Table 1 and Supplementary Table 1.

95 This algorithm can straightforwardly translate a projected number of total infections into an
 96 expected number of hospitalisations by age group. For a range of likely exposure levels over
 97 the next 6 months, we can estimate the respective expected mortality, as was done in¹², by
 98 applying the probabilities in Table 1 and following the branching processes in Figure 1. We
 99 make this estimate under two scenarios: (1) patients do not receive dexamethasone; (2)
 100 patients receive dexamethasone if they meet the criteria for the treatment as described in¹.

101 The number of potential lives saved by adopting dexamethasone as a standard COVID-19
 102 treatment is simply the difference between these figures. We estimate that, for the UK,
 103 approximately 12,000 (4,250 - 27,000 90% confidence interval) lives could be saved over the
 104 next 6 months (July-December 2020), under perfect access to treatment.

105 However, whilst in the UK it is reasonable to assume patients will have perfect access to
 106 whatever treatment they require, including dexamethasone, that assumption is
 107 unrealistic for many low and middle-income countries (LMICs). Of note, in scenarios where
 108 access to oxygen therapy or ventilatory support is limited, the effect of dexamethasone on
 109 patient outcome is unknown. It is therefore essential to perform clinical research in LMICs,
 110 where access to oxygen and ventilators is limited, to estimate the full potential of
 111 dexamethasone in the global fight against COVID-19.

112 To address this uncertainty, we simulated the use of dexamethasone if a patient meets the
 113 oxygen prescribing target described in¹³, whether or not oxygen is available. Whilst the
 114 impact of dexamethasone on patients who require but cannot access supplemental oxygen
 115 or invasive mechanical ventilation is not known, it is reasonable to assume that some
 116 mortality benefit would arise from the reduction of inflammation and consequent decrease

in the probability of progressing to respiratory failure. We estimated the potential number of lives saved under two assumptions: (1) dexamethasone has the same relative impact on mortality in patients who do not receive the respiratory support they require as in those who do; (2) dexamethasone has no impact on patient outcome if the patient does not receive the oxygen or ventilation they need. When including access to respiratory support as a covariate in the sensitivity analysis, we obtain an estimated approximately 650,000 (240,000 - 1,400,000 90% confidence interval) potential lives saved under the first assumption and 390,000 (130,000 - 1,000,000 90% confidence interval) lives saved under the second assumption.

Dexamethasone is an affordable drug that has been on the market for many years¹⁴. Its use can substantially alter outcomes for patients with COVID-19 and by doing so will impact hospital occupancy management and overall cost of treatment. Here, we also explore the economic ramifications of adopting dexamethasone as a default option for treating patients with COVID-19 and provide metrics for the cost-effectiveness of this conceivable health policy change in the UK. To accomplish this, we procured daily hospital patient costs per treatment given as well as data on length of hospital stay for patients with different hospital pathways and disease outcomes – see Methods for more details. According to National Institute for Health and Care Excellence (NICE) directives, interventions with an ICER of less than £20,000 per QALY or life year gained are considered to be cost effective¹⁸.

In the UK, we estimate a total incremental cost of £85,000,000 (£6,000,000 - £330,000,000 90% confidence interval) over the next 6 months, which equates to £8,200 (£650 - £17,500 90% confidence interval) per life saved and £760 (£52 - £1640 90% confidence interval) per life year gained, making dexamethasone treatment a clearly cost-effective option (**Error!**

Reference source not found.) We have refrained from presenting these estimates for the rest of the world due to the large variance in hospital patient management, hospitalisation costs, and access to treatment in other countries, and especially in LMICs.

Discussion

Dexamethasone is a globally accessible existing treatment that can be highly cost effective if given to hospitalised COVID-19 patients requiring oxygen therapy. Particularly in the UK setting, Dexamethasone is estimated to save up to 27,000 lives in the coming 6 months at a cost of up to £1640 per life year gained, which outshines the recently implemented HPV vaccination ICER¹⁹, e.g. In developed countries with an ageing population, where access to respiratory support is not expected to be an issue, Dexamethasone should promptly be adopted as standard treatment for patients with respiratory distress. This treatment, if given in accordance with the current guidance on patient eligibility for oxygen therapy, even where access to oxygen is limited, could save hundreds of thousands of lives in the coming six months of the pandemic. In settings where social distancing and other non-pharmaceutical interventions are becoming untenable, dexamethasone could serve both to reduce mortality and mitigate the burden on health systems.

Acknowledgements

We thank all members of the COVID-19 International Modelling Consortium and their collaborative partners. This work was supported by the COVID-19 Research Response Fund, managed by the Medical Sciences Division, University of Oxford. LJW is supported by the Li Ka Shing Foundation. RA acknowledges funding from the Bill and Melinda Gates Foundation (OPP1193472).

166 References

- 167 1 Horby, P. *et al.* Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.
168 *N Engl J Med*, doi:10.1056/NEJMoa2021436 (2020).
- 169 2 Kim, G. U. *et al.* Clinical characteristics of asymptomatic and symptomatic patients with mild
170 COVID-19. *Clin Microbiol Infect* **26**, 948.e941-948.e943, doi:10.1016/j.cmi.2020.04.040
171 (2020).
- 172 3 Docherty, A. B. *et al.* Features of 16,749 hospitalised UK patients with COVID-19 using the
173 ISARIC WHO Clinical Characterisation Protocol. *medRxiv*, 2020.2004.2023.20076042,
174 doi:10.1101/2020.04.23.20076042 (2020).
- 175 4 Chowdhury, R. *et al.* Dynamic interventions to control COVID-19 pandemic: a multivariate
176 prediction modelling study comparing 16 worldwide countries. *Eur J Epidemiol* **35**, 389-399,
177 doi:10.1007/s10654-020-00649-w (2020).
- 178 5 Cahan, E. *Drug recently shown to reduce coronavirus death risk could run out, experts warn*,
179 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
180 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
181 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
182 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
183 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
184 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
185 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
186 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
187 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
188 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
189 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
190 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
191 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
192 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
193 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
194 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
195 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
196 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
197 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
198 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
199 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
200 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
201 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
202 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
203 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
204 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
205 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
206 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
207 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
208 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
209 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
210 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
211 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
212 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
213 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)
214 <[https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-](https://www.sciencemag.org/news/2020/06/corticosteroid-drug-recently-shown-reduce-coronavirus-death-risk-could-run-out-experts)

215 21. Pollan et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based
216 seroepidemiological study. Lancet. 2020 Jul 3;S0140-6736(20)31483-5. doi: 10.1016/S0140-
217 6736(20)31483-5.

218 22. [https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_109_COVID-19.pdf)
219 [China/documentos/Actualizacion_109_COVID-19.pdf](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_109_COVID-19.pdf)

220

221

222

223 **Figure legends**

224

225 **Figure 1:** Patient pathway diagram for the calculation of COVID-19 mortality for a given
226 exposure level.

227 **Figure 2:** Expected impact of dexamethasone in the UK over the next six months for the
228 range of scenarios explored. The value and range quoted for each outcome represent the
229 median and 5th and 95th percentiles of the sensitivity analysis outcomes, i.e. 90% double-
230 sided confidence intervals.

231

Table 1: Definitions of the values used for the calculation and, where relevant, the ranges of values used for the sensitivity analysis.

Definition	Symbol	Value	Range		Source
			Lower	Upper	
Proportion of population expected to be exposed during the 6-month period	α	0.07	0.05	0.15	⁸
Level of access to appropriate respiratory support (as a proportion)	κ	1	0.5	1	-
Increase in fatality rate if no access to appropriate respiratory support	ψ	1	1	2	-
Probability of hospitalised patient needing oxygen (either non-invasive or ventilator)	p_{O_2}	0.76	0.2	0.9	¹
Probability of an hospitalised patient who receives oxygen needing a ventilator if on dexamethasone	p_{vd}	0.22* 0.87	0.04	0.5	¹
Probability of an infected patient who receives oxygen needing a ventilator if not on dexamethasone	p_v	0.22	0.05	0.6	¹
Maximum death probability for a hospitalised infection	δ_H	0.3	-	-	³
Maximum death probability for a hospitalised infection requiring non-invasive oxygen	δ_{O_2}	0.4	-	-	³
Maximum death probability for a hospitalised infection requiring a ventilator	δ_v	0.66	-	-	³
Reduction in mortality for patients requiring non-invasive oxygen if on dexamethasone	ϵ_{O_2}	0.2	-	-	¹
Reduction in mortality for patients requiring a ventilator if on dexamethasone	ϵ_v	0.36	-	-	¹
Incremental number of days spent in a general ward bed for a survivor that required non-invasive oxygen	ids_{O_2}	4.5	2	7	¹⁵
Incremental number of days spent in a general ward bed for a survivor that required ventilation	ids_v	5	3	8	¹⁵
Incremental number of days spent in an ICU bed for a survivor that required ventilation	idc_v	-1	-2	3	¹⁵

238 **Figure 1**

239

240

241 **Figure 2**

242

Infections	5% to 15% of the population
Hospitalizations	300,000 (160,000 to 430,000)
Total deaths	73,000 (40,000 to 110,000)
<i>With Dexamethasone</i>

£	Incremental cost	£ 85 m (£ 6 m to £ 330 m)
Lives saved	12,000 (4,250 to 27,000)
Life Years Gained	126,000 (46,000 to 290,000)
ICER = incremental cost per life-year gained	£ 760 (£ 52 to £ 1640)

243

244

245

Online Methods

We calculate the population expected to be exposed in each age class by multiplying the proportion of population expected to be exposed during the 6-month period, α , (**Error! Reference source not found.**) by the number of people in each age group, n (Supplementary Table 1). We obtain the number of people expected to require hospitalisation by multiplying the previous figure by the age structured proportion of all exposures leading to hospitalisation, p_H , (Supplementary Table 1). We then multiply this vector by various combinations of probabilities depending on the within-hospital patient pathway (Figure 1), structured by normalised hospitalisation fatality rate, p_F , (Supplementary Table 1) as follows:

- Expected deaths in hospitalised patients that do not require oxygen (either non-invasive or ventilator) in each age category:

$$y_H = \alpha n p_H p_F (1 - p_{O_2}) [\kappa + (1 - \kappa)(1 + \psi)] \delta_H \quad \text{Equation 1}$$

- Expected deaths in hospitalised patients who require non-invasive oxygen and receive dexamethasone in each age category:

$$y_{O_2} = (1 - \epsilon_{O_2}) \alpha n p_H p_F p_{O_2} [\kappa(1 - p_V) + (1 - \kappa)(1 - p_V)(1 + \psi)] \delta_{O_2}$$

Equation 2

- Expected deaths in hospitalised patients who require mechanical ventilation and receive dexamethasone in each age category:

$$y_V = (1 - \epsilon_V) \alpha n p_H p_F p_{O_2} p_{Vd} [\kappa^2 + (1 - \kappa)(1 + \psi) + \kappa(1 - \kappa)(1 + \psi)] \delta_V$$

Equation 3

Then, the expected number of deaths in patients in each age category with severe respiratory distress that receive dexamethasone is given by:

$$y_D = y_H + y_{O_2} + y_V \quad \text{Equation 4}$$

The expected number of deaths in each age category in the same patients if they do not receive dexamethasone is:

$$y_0 = y_H + \frac{y_V p_V}{(1 - \epsilon_V) p_{Vd}} + \frac{y_{O_2}}{(1 - \epsilon_{O_2})} \quad \text{Equation 5}$$

The potential lives saved, summed over all age categories, is then given by $\sum y_L$ where:

$$\sum y_L = \sum (y_o - y_D) \quad \text{Equation 6}$$

The model follows the disease pathway of COVID-19-infected patients with severe respiratory illness requiring hospitalization, non-invasive oxygen and mechanical ventilation. Depending on the strategies under investigation, patients may or may not be further split by type of management (general ward versus ICU) and use of medication (e.g. dexamethasone). In short, a proportion p_{O_2} of individuals admitted to hospital with respiratory distress will require some form of oxygen. A subset of those, p_{Vd} , will need mechanical ventilation. If people have perfect access to the treatment they require, their outcome is determined by a treatment specific, age-dependent probability of death. This is calculated by multiplying the age-dependent mortality modulation vector p_F (Supplementary Table 1) by the appropriate treatment requirement death probabilities in Table 1. If access to oxygen and/or ventilation is not perfect, the patient will not receive the most appropriate treatment, which will be reflected in an increase in mortality probability given by ψ . Prompt treatment with dexamethasone is assumed to reduce the need for patient ventilation by 13%, p_{Vd} .

The costing analysis makes use of the simple state transition modelling framework described above (and illustrated in Figure 1). The analysis takes a provider (health system) perspective. Costs are expressed in 2020 prices, and no discounting is undertaken given that all costs within the analyses are incurred within a short period of time. The models include two absorbing states: recovered and dead. The former is assumed to have no morbidity loss (i.e. patients return to their pre-COVID-19 health state upon recovery) while the latter captures the years of life lost (YLL) for a person dying of COVID-19. The YLL associated with

295 death is taken from secondary data and is based on estimated life expectancy for UK citizens
296 in each of the five-year age groups¹⁶.

297 From the patient pathway model in Figure 1, we can extrapolate hospital utilisation,
298 including the proportion of hospitalised individuals occupying ICU vs surge beds. To
299 calculate hospitalisation costs per patient hospital pathway, we then need to know the
300 length of stay per patient in each type of hospital bed. We assume that patients requiring
301 oxygen alone will only occupy surge beds during their stay, regardless of outcome. However,
302 patients that do recover spend on average 4.5 more days in hospital than those who
303 die^{15,20}. Patients needing mechanical ventilation will occupy ICU beds for an average of 7
304 days if they survive and then spend an extra 5 days on average in a surge bed¹⁵. Ventilated
305 patients who eventually die typically spend 8 days in an ICU bed. We then use the
306 incremental number of days spent in hospital, together with unit cost data per inpatient day
307 in surge beds and intensive care beds, taken from the NHS National Tariff¹⁷, to inform the
308 total incremental cost of lives saved and life years gained. The costs used are provided in
309 Supplementary Table 2. To assess the cost-effectiveness of dexamethasone treatment, we
310 need to compute the additional cost of hospital treatment including dexamethasone as
311 compared with the cost of treatment without dexamethasone, known as the incremental
312 cost-effectiveness ratio (ICER). To calculate the ICER, the cost of providing dexamethasone is
313 subtracted from the cost of treatment without dexamethasone and divided by the
314 difference in YLL for the two treatment arms (no dexamethasone vs dexamethasone). The
315 difference between the YLL for the two treatment arms then becomes the years of life
316 gained (YLG).

317
$$ICER = \frac{\text{incremental cost of providing dexamethasone}}{\text{life years gained}} \quad \text{Equation 7}$$

318 To reflect the uncertainty inherent to the estimated numbers of deaths prevented, life years
319 gained, total incremental cost, incremental cost per life saved, and incremental cost per life
320 year gained, we perform sensitivity analyses through Latin-hypercube sampling. Simply put,
321 we iteratively calculate our interest outcome variables, where at each iteration we sample a
322 value for selected input values from uniform distributions with set intervals, with ranges
323 given in Table 1. For all sensitivity analyses we perform 1 million iterations and present the
324 results as median and 5th and 95th percentiles, i.e. the 90% double-sided confidence
325 intervals. Throughout the manuscript, we presented epidemiological and costing estimates
326 calculated when assuming the infection hospitalisation ratio (IHR) and the hospitalisation
327 fatality ratio (HFR) in the UK resemble that estimated from French data¹⁰. Ideally, we would
328 use UK age-dependent serology data to inform a UK specific IHR. Unfortunately, those data
329 are not currently available so we must rely on other countries estimates/data. Whilst we
330 believe the French estimates are a good reflection of the UK reality, we re-calculate all
331 estimates (Supplementary Table 3), assuming HFR and HFR to follow age patterns similar to
332 those measured in Spain (Supplementary Table 4).

333
334
335
336
337

338 **Supplementary Table 1. Age structured values for the UK population, n^9 , the infection**
 339 **hospitalisation rate, p_H^{10} , and the normalised hospitalisation fatality rate, p_F^{10} .**

Age group (years)	Population (n)	p_H	p_F
0-4	3,924,490	0.002	0.019
5-9	4,119,566	0.002	0.019
10-14	3,956,340	0.002	0.019
15-19	3,686,133	0.002	0.019
20-24	4,074,640	0.006	0.035
25-29	4,484,067	0.006	0.035
30-34	4,706,828	0.013	0.060
35-39	4,588,196	0.013	0.060
40-44	4,308,130	0.017	0.10
45-49	4,296,121	0.017	0.10
50-54	4,634,540	0.035	0.21
55-59	4,538,925	0.035	0.21
60-64	3,905,016	0.071	0.40
65-69	3,381,761	0.071	0.40
70-74	3,388,488	0.113	0.66
75-79	2,442,147	0.113	0.66
80-84	1,736,567	0.32	1
85-89	1,077,555	0.32	1
90-94	490,577	0.32	1
95-99	130,083	0.32	1
100+	15,834	0.32	1

340

341

342 **Supplementary Table 2: Cost inputs and assumptions used.**

Variable	Value (GBP)
Dexamethasone treatment course	5.00
Cost per day for patients on mechanical ventilation in an ICU	4,520.00
Cost per day for patients on non-invasive ventilation with oxygen	1,356.00
Incremental number of days spent in hospital by survivors	4.5

343

344

Supplementary Table 3: Sensitivity of the main epidemiological and costing metrics to assumptions on the infection hospitalisation rate, p_H , and the normalised hospitalisation fatality rate, p_F . The two countries from which p_h and p_f vectors are derived, and corresponding median and 90% confidence intervals are shown in columns.

	<i>France</i>	<i>Spain</i>
<i>Lives Saved</i>	12,000 [4,250 – 27,000]	5,200 [2,000 – 12,000]
<i>Life Years Gained</i>	126,000 [46,000 – 290,000]	60,000 [20,500 – 134,000]
<i>Total Incremental Cost (£)</i>	84,500,000 [5,700,000 – 330,000,000]	37,500,000 [2,500,000 – 143,300,000]
<i>Incremental Cost per Life Saved (£)</i>	8,230 [565 – 17,700]	8,200 [650 – 17,500]
<i>Incremental Cost per Life Year Gained (£)</i>	760 [52 – 1,640]	720 [50 – 1,550]

354 **Supplementary Table 4. Infection hospitalisation rate, $p_H S$, and the normalised**
 355 **hospitalisation fatality rate, $p_F S$ derived from Spanish data^{21,22}.**

Age group (years)	$p_H S$	$p_F S$
0-4	0	0
5-9	0	0
10-14	0.001	0
15-19	0.001	0
20-24	0.005	0.038
25-29	0.005	0.038
30-34	0.012	0.041
35-39	0.012	0.041
40-44	0.016	0.055
45-49	0.016	0.055
50-54	0.030	0.103
55-59	0.030	0.103
60-64	0.048	0.234
65-69	0.048	0.234
70-74	0.078	0.533
75-79	0.078	0.533
80-84	0.121	1
85-89	0.121	1
90-94	0.121	1
95-99	0.121	1
100+	0.121	1

356

357

358

359 CoMo Consortium authors

Name	Email	Affiliation
Fatima Arifi	fatima.arefi@gmail.com	World Health Organization, Kabul, Afghanistan
Chynar Zhumaliev	cjumaliev@gmail.com	Public fund «Institution of social development»
Inke N D Lubis	inkenadia@gmail.com	Department of Paediatrics, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Antoninho Benjamin Monteiro	abemorio_medicine@yahoo.com	Universidade da Paz, Timor-Leste
Ainura Moldokmatova	ainura.moldokmatova@ndm.ox.ac.uk	Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford
Ricardo Aguas	ricardo.aguas@ndm.ox.ac.uk	Nuffield Department of Medicine, Mahidol-Oxford Tropical Medicine Research Unit, University of Oxford
Siyu Chen	2735953203@qq.com	Nuffield Department of Medicine, University of Oxford
Aida Estevesova	aestesova@usaid.gov	USAID Mission in the Kyrgyz Republic
Moofakhar Hussain	mofakhar.hussain@utoronto.ca	IHPME, University of Toronto
Dipti Lata	dipti.lata@opml.co.uk	Oxford Policy Management (OPM) Nepal
Bakare Emmanuel A.	emmanuel.bakare@fuoye.edu.ng	Department of Mathematics, Federal University, Oye-Ekiti, Ekiti State, Nigeria.
Biniam Getachew	biniongech@gmail.com	Stop Transmission of Polio Program (STOP) program, World Health Organization, Birnin Kebbi, Nigeria
Mohammad Nadir Sahak	sahakm@who.int	World Health Organization, Kabul, Afghanistan
Phetsavanh Chanthavialy	phetsavanh456@gmail.com	Institute of Research and Education Development, University of Health Sciences, Lao PDR
Akindeh M. Nji	akindeh@gmail.com	Laboratory for Public Health Research biotechnology, Biotechnology Center, University of Yaounde I
Yu Nandar Aung	dr.yu.ndaung@gmail.com	London School of Economics
Nathaniel Hupert	nah2005@med.cornell.edu	Department of Medicine, Weill Cornell Medicine, and Cornell Institute for Disease and Disaster

		Preparedness, Cornell University, USA
Sai Thein Than Tun	Sai@tropmedres.ac	1: Mathematical And Economic MODelling Group, Mahidol-Oxford Tropical Medicine Research Unit; 2: Nuffield Department of Medicine, University of Oxford
Wirichada Pan-ngum	pan@tropmedres.ac	Mathematical And Economic MODelling Group, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
Sarin KC	sarin.k@hitap.net	Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Thailand
Handoyo Harsono	handoyoharsono@gmail.com	COVID-19 Task Force for North Sumatera province, Indonesia
Sana Eybpoosh	sana.eybpoosh@gmail.com	Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran
Renato Mendes Coutinho	renato.coutinho@ufabc.edu.br	Center for Mathematics, Computation and Cognition, Federal University of ABC, Brazil
Semeeh A. Omoleke	talk2semeeh@gmail.com	World Health Organization, Nigeria
Amen-Patrick Nwosu	amen-patrick.nwosu@ndm.ox.ac.uk	Nuffield Department of Medicine, University of Oxford
Nantasit Luangasanatip	Nantasit@tropmedres.ac	Mathematical And Economic MODelling Group, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
Ainura Kutmanova	kutmanova@yahoo.com	Ministry of Public Health of the Kyrgyz Republic
Dooronbekova Aizhan	aizhan.dooronbekova@gmail.com	Public fund «Institution of social development»
Antonio Ximenes	ximenes085@gmail.com	Universidade Nacional Timor Lorosae, Timor-Leste
Merita Monteiro	methamonteiro@yahoo.com	Charles Darwin University
Olivier Celhay	olivier.celhay@gmail.com	Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
Keyrellous Adib	adibk@who.int	Independent researcher (No affiliation)

Rima Shretta	rima.shretta@ndm.ox.ac.uk	Nuffield Department of Medicine, University of Oxford
Amel H. Salim	amalahshugairy@gmail.com	Population Services International/Ethiopia
Yuki Yunanda	yukiyunanda@gmail.com	Department of Community Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Mahnaz Hossain Fariba	faribamahnaz@gmail.com	Government of People's Republic of Bangladesh (ex. Nuffield Department of Medicine, University of Oxford)
Amirah Azzeri	amirah.azzeri@ummc.edu.my	Department of Research, Development and Innovation, University Malaya Medical Centre
Penny Hancock	penny.hancock@bdi.ox.ac.uk	Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford
Hakim Bekrizadeh	h_bekri@yahoo.com	Department of Statistics, Payame Noor University
Sayed Ataullah Saeedzai	atasayedzai@gmail.com	Ministry of Public Health, Afghanistan
Ivana Alona	ivanaalona@gmail.com	Department of Community Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Grace Wezi Mzumara	g.wezimzumara@gmail.com	Malawi Ministry of Health
Joao Martins	joasmartins@hotmail.com	Universidade Nacional Timor Lorosae, Timor-Leste
Jose L. Herrera-Diestra	diestra@gmail.com	Centro de Simulacion y Modelos (CeSiMo). Universidad de Los Andes. Merida - Venezuela
Hamid Sharifi	sharifhami@gmail.com; hsharifi@kmu.ac.ir	HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
Talant Abdyl daev	kumbel1@yandex.ru	Kyrgyz Medical Association
Babak Jamshidi	b-jamshidi@phdstu.scu.ac.ir	Department of Biostatistics, Kermanshah University of Medical Sciences
Noran Naqiah Hairi	noran@um.edu.my	University of Malaya, Malaysia
Naima Nasir	ms.naimanasir@gmail.com	Center for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
Rashid U Zaman	rashid.zaman@opml.co.uk	Oxford Policy Management
Sopuruchukwu	sopuruchukwu.obiesie@oriel.ox.ac.uk	Center for Tropical Medicine and

Obiesie		Global Health, Nuffield Department of Medicine, University of Oxford
Roberto A. Kraenkel	roberto.kraenkel@unesp.br	Institute for Theoretical Physics - São Paulo State University (UNESP)
Nicholas Letchford	nicholas.letchford@opml.co.uk	Oxford Policy Management
Lucsendar Raimunda Fernandes Alves	sendinha@hotmail.com	Menzies School of Health Research, Charles Darwin University
Sandra Adele	sandra.adele@ndm.ox.ac.uk	Nuffield Department of Medicine, University of Oxford
Lorena Suárez-Idueta	suarezidueta@gmail.com	Univesity College of London
Nicole Advani	nicole.advani@ndm.ox.ac.uk	Nuffield Department of Medicine, University of Oxford
Manar Marzouk	manar_marzook@hotmail.com	Valid International Ltd
Viviana Mabombo	viviana.mabombo@wolfson.ox.ac.uk	Nuffield Department of Medicine, University of Oxford
Aibek Mukambetov	amukambetov@soros.kg	Soros Foundation in the Kyrgyz Republic
Adeniyi Kolade Aderoba	adeniyi.aderoba@gmail.com	Center for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
B Priya Lakshmy TBalasubramaniam	priya.tbalasubramaniam@ndm.ox.ac.uk	Nuffield Department of Medicine, University of Oxford
Nicole Feune de Colombi	nicole.feunedecolombi@ndm.ox.ac.uk	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
Maria Angela Varela Niha	nihamaria20@gmail.com	Ministry of Health Timor-Leste
Francisco Obando	francisco.obando@compas.ox.ac.uk	PEAK Urban and Oxford Martin Informal Cities Programmes, COMPAS, School of Anthropology and Museum Ethnography, University of Oxford
Parinda Wattanasri	parinda.wattanasri@ndm.ox.ac.uk	1:Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford 2:Department of Disease Control, Ministry of Public Health, Thailand
Sompob Saralamba	Sompob@tropmedres.ac	Mathematical And Economic MODelling Group, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
Fatiha	fatiha.shabaruddin@um.edu.my	Faculty of Pharmacy, University of

Shabaruddin		Malaysia
Shafiun Nahin Shimul	shafiun.ihe@du.ac.bd	Institute of Health Economics, University of Dhaka, Bangladesh
Maznah Dahlui	maznahd@ummc.edu.my	Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya
Reshania Naidoo	reshania.naidoo@ndm.ox.ac.uk	Center for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
Caroline Franco	c.franco@unesp.br	Institute of Theoretical Physics - São Paulo State University (UNESP)
Michael G. Klein	michael.klein@sjsu.edu	Department of Marketing & Business Analytics, Lucas College and Graduate School of Business, San José State University, USA
Aisuloo Kubatova	kubatova.aisuloo@gmail.com	Public fund Institution of social development
Manar Marzouk	manar_marzook@hotmail.com	Valid International Ltd
Nusrat Jabin	nusrat.jabin@ndm.ox.ac.uk	Nuffield Department of Medicine, University of Oxford
Lisa J White	lisa.white@ndm.ox.ac.uk	Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford
Shwe Sin Kyaw	shwesin@tropmedres.ac	Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University
Luzia Tomas Freitas	luzia.freitas@ndm.ox.ac.uk	Center for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
Sunil Pokharel	sunildrp@gmail.com	Nuffield Department of Medicine, University of Oxford
Proochista Ariana	proochista.ariana@ndm.ox.ac.uk	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
Chris Erwin G. Mercado	cegmercado@gmail.com	Independent Researcher
Shamil Ibragimov	shamil@soros.kg	Soros Foundation in the Kyrgyz Republic
John Robert C. Medina	jcmolina1@up.edu.ph	Department of Epidemiology and Biostatistics, College of Public Health, University of the Philippines Manila, Philippines
Dr. Mesulame Namedre		Fiji CDC